BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Sigma-Tau Group 

9841 Washingtonian Boulevard
Suite 500
Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-948-1041 Fax: 301-948-1862


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Dyax Corp.  Ecallantide in HAE and other therapeutic indications





 Company News
Sigma-Tau Group : A New Efficient and Cost Effective Dialysis for Patients With End Stage Renal Disease 6/18/2013 12:21:31 PM    More...
SciClone Pharmaceuticals, Inc. (SCLN) Files S-3 Registration Statement Prospectus Supplement Related to Sigma-Tau Group Transaction 4/30/2012 8:49:39 AM    More...
Dyax Corp. (DYAX) and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema 1/12/2011 10:16:40 AM    More...
Dyax Corp. (DYAX) and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema 1/11/2011 10:58:48 AM    More...
Enzon Pharmaceuticals, Inc. (ENZN) Stockholders Approve Sale of Specialty Pharmaceutical Business to Sigma-Tau Group 1/28/2010 9:05:14 AM    More...
SciClone Pharmaceuticals, Inc. (SCLN) and Sigma-Tau Group Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine 1/12/2010 11:40:59 AM    More...
Gentium S.p.A. Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-Tau Group 1/11/2010 9:42:03 AM    More...
SciClone Pharmaceuticals, Inc. (SCLN) Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau Group 12/1/2009 11:20:40 AM    More...
Enzon Pharmaceuticals, Inc. (ENZN) to Sell Specialty Pharmaceuticals Business to the Sigma-Tau Group for $300 Million Plus up to $27 Million 11/9/2009 7:47:07 AM    More...

//-->